DAVID GOEDDEL

David Goeddel stands as a towering figure in the biotechnology and life sciences landscape, renowned for his dual expertise as a pioneering molecular biologist and a highly successful venture capitalist. As a Managing Partner at The Column Group (TCG), he plays a pivotal role in shaping the future of medicine by identifying, co-founding, and nurturing innovative early-stage biotech companies. His unique approach combines deep scientific insight with strategic investment acumen, driving the development of transformative therapies.

At The Column Group, David Goeddel's investment focus is sharply honed on groundbreaking science with the potential to address significant unmet medical needs. TCG operates with a distinctive model, often acting as scientific co-founders alongside leading academics and entrepreneurs. Goeddel specifically targets companies engaged in novel drug discovery and therapeutic development across a spectrum of diseases, including oncology, neurodegeneration, immunology, and metabolic disorders. He seeks out ventures that leverage cutting-edge platforms and bold scientific hypotheses to create first-in-class or best-in-class medicines.

Goeddel's illustrious career began at Genentech, where he was employee number eight and a foundational scientist. His groundbreaking work in recombinant DNA technology revolutionized the pharmaceutical industry. He was instrumental in the cloning and expression of critical human proteins, including insulin, human growth hormone, and various interferons, laying the groundwork for many modern biotech drugs. This pioneering research earned him widespread recognition, including membership in the National Academy of Sciences and the prestigious Lasker Award, often referred to as "America's Nobel."

Following his impactful tenure at Genentech, Goeddel co-founded Tularik, a biotechnology company focused on gene regulation, which was later acquired by Amgen. This entrepreneurial success further solidified his reputation as a visionary leader capable of translating scientific discoveries into viable commercial enterprises. His transition to venture capital with The Column Group allowed him to scale this impact, enabling him to mentor and build numerous companies from inception. Notable companies he has helped establish and guide include Denali Therapeutics, focused on neurodegenerative diseases; NGM Biopharmaceuticals, developing therapies for metabolic, liver, and ophthalmic diseases; Arcus Biosciences, a leader in cancer immunotherapy; and Carmot Therapeutics, recently acquired by Roche for its metabolic disease pipeline.

David Goeddel's influence extends beyond capital investment; he is deeply involved in the scientific strategy and operational development of TCG's portfolio companies. His unparalleled experience, from the lab bench to the boardroom, provides invaluable guidance to nascent biotech ventures. He embodies the rare combination of a world-class scientist and a shrewd business strategist, making him an indispensable force in the biotechnology ecosystem. His enduring commitment to advancing human health through scientific innovation continues to drive the creation of new medicines and shape the future of the life sciences industry.